Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

NCT05618028 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05618028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05618028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 4, 2023
Completion date
July 31, 2029
Enrollment
78 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

b cell malignancies, chronic lymphocytic leukemia, diffuse large b-cell lymphoma, non-hodgkin's lymphoma